CannPal

CannPal

45a Bay Street Double Bay NSW

CannPal Animal Therapeutics Limited is a listed animal health company selling cannabinoid derived therapeutics for companion animals. They develop innovative and naturally derived plant-based products with safe and scientifically validated methods.

Their research is focused on cannabinoids, the active pharmaceutical ingredients extracted from the cannabis plant, to provide clinically validated and standardised therapeutics for safe and ethical animal treatment.

Current medications available to pets for treatment often have side effects such as nausea, loss of appetite, depression and internal bleeding. Human drugs are often repurposed for pet use to try and meet unmet needs, but more needs to be done to treat pets in a safe and ethical way.

CannPal works to explore the natural healing abilities of compounds that can effectively treat pets to improve their quality of life without negative side effects. Their active product pipeline involves two lead products in development targeting pain and inflammation in dogs as well as canine skin health. They are researching cannabidiol (CBD) and Delta-9 Tetrahydrocannabinol (THC), but they are also researching other cannabinoid-like compounds derived from the cannabis plant.

One of CannPal’s three main products in the research and development stage is a cannabis-derived therapeutic product that targets pain and inflammation in companion animals, with a focus on dogs. They hope that this product will replace the use of NSAIDs, the most common treatment for pain in dogs as NSAIDs have a long list of negative side effects and they are not suitable for long term use. They also have a range of nutraceutical products in development for canine skin conditions, and a drug delivery system in the works.

For more information, give CannPal a call at +61 (2) 6108 3622 or email them at [email protected]. They can be found at Level 3, 45a Bay Street, Double Bay, NSW 2028 Australia.


Industry: Medical Cannabis

Sub Industry: Animals,ASX-Listed

About (30 words): CannPal Animal Therapeutics Limited (ASX:CP1) is developing plant-based animals therapeutics targeting the endocannabinoid system in pets.

See all the Australian cannabis & hemp companies
Weekly Cannabis News

Get the latest Australian cannabis news straight to your inbox every week.